Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.


Journal

SLAS discovery : advancing life sciences R & D
ISSN: 2472-5560
Titre abrégé: SLAS Discov
Pays: United States
ID NLM: 101697563

Informations de publication

Date de publication:
01 2020
Historique:
pubmed: 10 9 2019
medline: 23 9 2020
entrez: 10 9 2019
Statut: ppublish

Résumé

Cell-based phenotypic screening is a commonly used approach to discover biological pathways, novel drug targets, chemical probes, and high-quality hit-to-lead molecules. Many hits identified from high-throughput screening campaigns are ruled out through a series of follow-up potency, selectivity/specificity, and cytotoxicity assays. Prioritization of molecules with little or no cytotoxicity for downstream evaluation can influence the future direction of projects, so cytotoxicity profiling of screening libraries at an early stage is essential for increasing the likelihood of candidate success. In this study, we assessed the cell-based cytotoxicity of nearly 10,000 compounds in the National Institutes of Health, National Center for Advancing Translational Sciences annotated libraries and more than 100,000 compounds in a diversity library against four normal cell lines (HEK 293, NIH 3T3, CRL-7250, and HaCat) and one cancer cell line (KB 3-1, a HeLa subline). This large-scale library profiling was analyzed for overall screening outcomes, hit rates, pan-activity, and selectivity. For the annotated library, we also examined the primary targets and mechanistic pathways regularly associated with cell death. To our knowledge, this is the first study to use high-throughput screening to profile a large screening collection (>100,000 compounds) for cytotoxicity in both normal and cancer cell lines. The results generated here constitute a valuable resource for the scientific community and provide insight into the extent of cytotoxic compounds in screening libraries, allowing for the identification and avoidance of compounds with cytotoxicity during high-throughput screening campaigns.

Identifiants

pubmed: 31498718
doi: 10.1177/2472555219873068
pii: S2472-5552(22)06521-2
doi:

Substances chimiques

Antineoplastic Agents 0
Small Molecule Libraries 0

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

9-20

Auteurs

Olivia W Lee (OW)

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

Shelley Austin (S)

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

Madison Gamma (M)

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

Dorian M Cheff (DM)

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

Tobie D Lee (TD)

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

Kelli M Wilson (KM)

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

Joseph Johnson (J)

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

Jameson Travers (J)

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

John C Braisted (JC)

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

Rajarshi Guha (R)

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

Carleen Klumpp-Thomas (C)

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

Min Shen (M)

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

Matthew D Hall (MD)

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH